Influenza Vaccines Market Diagnosis, Treatments and Global Key Players 2027

 Market Overview:

The influenza vaccines market is expected to grow at a 6.53 percent CAGR by 2025, reaching USD 7,828.3 million. Humans are vulnerable to the influenza virus, a highly contagious and lethal virus that can infect their respiratory systems. Influenza is a viral respiratory infection that affects the lungs, nose, and throat. People who are chronically unwell or have weakened immune systems are most vulnerable. A viral illness that causes nasal and pulmonary leakage spreads from person to person. Vaccines help to prevent illnesses by boosting the body's natural defenses. Vaccines stimulate the body's creation of antibodies that help it fight illnesses. Most diseases are protected against by vaccination for several years, decades, or even a lifetime. Vaccinations are the most effective way to keep influenza viruses from infecting humans. It is predicted that the influenza vaccine market would reach $6.20 billion by 2026.

The influenza vaccine market is expected to reach $3.96 billion in 2018, with an annual growth rate of 5.9 percent (CAGR) from 2019 to 2026. Between 2019 and 2020, the Centers for Disease Control and Prevention recorded over 13 million documented flu cases. Depending on the current market scenario for influenza vaccinations, government agencies, the Centers for Disease Control and the World Health Organization suggest a licensed seasonal vaccine. Big pharmaceutical companies and organizations are always working to improve the effectiveness of vaccinations against various diseases caused by influenza, which has, in the past, resulted in deaths and turn, led to an upsurge in the influenza vaccine market value.

Industry News:

Profit, sales, and market income are all sources of revenue for market players. The following businesses dominate the influenza vaccines market: GlaxoSmithKline PLC (UK), Abbott Laboratories (US), Seqirus (UK), Mylan NV (US), AstraZeneca (UK), Hualan Biological Engineering Inc. (China), Mitsubishi Tanabe Pharma (Japan), and Serum Institute of India Pvt. Ltd. (India).

Market Segmentation:

By End-Users: They are divided into two primary types. The recombinant influenza vaccine, for example, is available for the elderly and adults. The alternative option is a trivalent vaccination, which is available for children aged 6 months and up

By application: The worldwide influenza vaccine varies depending on numerous aspects and the end goal. Users Individuals from academic institutes, hospitals, clinics, organizations, researchers, and others may be end-users of influenza vaccines in India vaccinations. The research industry is expected to grow throughout the anticipated period. It is driven by the virus's dynamic and changing nature, which mutates every year, and as a result, vaccinations need to be revised every six to twelve months.

Regional Classification:

The influenza vaccine market is divided into four regions: Europe, America, the Middle East, Africa, and Asia-Pacific. America, with a population of more than half a billion people, is leading the influenza vaccination industry. Every year, the influenza virus affects 5% to 20% of the whole population. European markets were the second-largest market for influenza vaccinations throughout the assessment period. The widespread nature of influenza, along with rising product demand, has fueled expansion in the regional market.

About US:

Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

Contact us:

Market Research Future (part of Wantstats Research and Media Private Limited),

99 Hudson Street,5Th Floor, New York,

New York 10013

United States of America

Biosimulation Market | Projected to Grow Radiantly by Top Players Revenue and Growth Rate by 2027

 Market Highlights

According to MRFR analysis, Biosimulation Market is expected to register a CAGR of 15.9% during the forecast period of 2019 to 2025 and is likely to be valued at USD 4.4 Billion by 2025. 

Biosimulation is a tool used for the prediction of the outcomes of existing clinical trials associated with innovation and new drug development.

The growth of the Global biosimulation Market is determined by numerous factors such as the growing adoption of biosimulation software by regulatory bodies, increasing healthcare expenditure, increasing use of pharmacokinetic & pharmacodynamic modelling in pre-clinical development and rising need to reduce the drug development costs. However, lack of standardization in biosimulation methodology and lack of trained professionals for monitoring biosimulation software are likely to hamper the growth of the global biosimulation market during the forecast period. 

Several market players currently dominate the Global Biosimulation Market. The key players are involved in product launches and strategic collaborations to strengthen their market positions. For instance, in September 2019, Certara Inc. launched version 8.2 of Phoenix, the most advanced and widely used validated software for PK, PD, and toxicokinetic modeling and simulation worldwide.

Key Players

Some of the Key Players in the Global Biosimulation Market are Dassault Systèmes (France), Certara USA, Inc. (US), Simulation Plus (US), Schrödinger (US), Chemical Computing Group (Canada), Physiomics (UK), In Silico Biosciences (US), Advanced Chemistry Development, Inc. (Canada), Genedata AG (Switzerland), Nuventra Pharma (US), Evidera (US), Leadinvent Technologies (India), LeadScope, Inc. (US), Rosa (US) and INOSIM Software GmbH (Germany).

Segmentation

The Global Biosimulation Market has been segmented based on product, application, delivery model and end users.

The market, based on product, has been divided into software and services. The software segment is further segmented into PK/PD (pharmacokinetic/pharmacodynamic) modeling and simulation software, molecular modeling and simulation software, PBPK (physiologically based pharmacokinetic) modeling and simulation software, toxicity prediction software, trial design software, and others. The services segment is further segmented into in-house services and contract services. The software segment is likely to hold the maximum market share in the global biosimulation market owing to growing adoption of biosimulation software by pharmaceutical and research organizations and the increasing R&D investment for pharmaceutical research.

The global biosimulation market based on the application has been segregated into drug development, drug discovery, and others. The drug development segment is expected to hold a larger share of the market share owing to the rising adoption of biosimulation tool for the drug development process.

The delivery model segment of the market is divided into subscription models and ownership models.

Based on end users, the global biosimulation market has been segmented into pharmaceutical and biotechnology companies, contract research organizations, research institutes, regulatory authorities, and others. Rising adoption of inorganic growth strategies by different biosimulation service providers is likely to boost the adoption of biosimulation solutions in the pharmaceuticals and biotechnology companies.

Regional Analysis

The market has been divided, by region, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa.

Americas has been segmented into North America and Latin America, with the North American market being divided into the US and Canada. The Americas is projected to hold the largest market share owing to the increasing R&D spending by pharmaceutical and biotechnology companies in the region and growing number of clinical trials & drug development practices. 

The European biosimulation market has been categorized as Western Europe and Eastern Europe. The Western European market has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe. The biosimulation market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. Rising geriatric population and the presence of a large patient pool, are the key factors responsible for the fastest growth of the market in Asia-Pacific. The biosimulation market in the Middle East & Africa has been divided into the Middle East and Africa.

About US:

Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

Contact us:

Market Research Future (part of Wantstats Research and Media Private Limited),

99 Hudson Street,5Th Floor, New York,

New York 10013

United States of America

AR & VR in Healthcare Market Segments, Key Players Strategies, Analysis and Forecasts Till 2027

 Market Overview

AR & VR in Healthcare Market is expected to grow at a CAGR of 27.30% during the forecast period. Virtual reality technology benefits both doctors and patients since it allows patients to virtually visit doctors, which is very convenient. This has propelled the growth of the VR market in the healthcare business to a large extent. VR technology is ahead of Augmented Reality due to its expanded capabilities. Virtual reality allows users to immerse themselves in another environment and interact with it in real-time. In contrast, AR produces a visual environment around you but does not allow you to interact with it. New start-ups keen to capitalize on this extensively utilized technology are among the factors fueling the growth of AR & VR in the Healthcare Market.

By combining AR and VR technology into new applications and adding new features to existing products, these start-ups are growing their AR and VR application portfolios. Product pricing has been lowered as a result of the widespread availability of VR and AR devices, as well as the growing number of enterprises working with the technology. To gain a competitive advantage, businesses have reduced their prices, making healthcare services cheaper. Businesses will also benefit from such measures as they adopt this technology. COVID-19 has had an unprecedented and stunning global impact, with demand for virtual reality in healthcare dropping across the board as a result of the outbreak.

Industry News

The major key players in the market are Atheer, Augmedix, Daqri, Firsthand Technology, Google, Medical Realities, Microsoft, Mindmaze, Oculus VR, Psious, EchoPixel, Inc., Osso VR Inc., Surgical Theater, LLC, Orca Health, Inc., Hologic Inc., and 3D Systems, Inc.

Market Segmentation

Based on the Technology, the global AR & VR Healthcare Market is segmented into VR technology and AR technology.

Based on the Application, the global AR & VR Healthcare Market is segmented into Patient care management, Fitness management, Medical training & education, Surgery, Pharmacy management, and Others.

Based on the Offerings, the global AR & VR Healthcare Market is segmented into Software and Hardware components.

Based on the Device Type, the global AR & VR Healthcare Market is segmented into VR device type and AR device type.

Based on the End-users, the global AR & VR Healthcare Market is segmented into Surgical centers, Hospitals & clinics, Research & academic institutes, Pharmaceutical companies, and Others.

Based on the region, the global AR & VR Healthcare Market is segmented into North America, Europe, Asia-Pacific, and the Rest of the World.

Regional Classification

Based on regional divisions, the virtual and augmented reality in healthcare has been divided into Europe, the Americas, the Middle East & Africa, and Asia-Pacific. Due to the increasing demand for healthcare cost reduction, the American market is predicted to lead AR & VR in healthcare by generating a greater market share during the forecast period. With the use of the AR guidance system, minimally invasive surgical operations in the United States save roughly USD 288 million. Furthermore, due to significant technological breakthroughs and increased financing for research, the European AR and VR Healthcare Market ranked second in terms of revenue generation during the historic forecast period of the AR & VR Healthcare Market.

About US:

Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

Contact us:

Market Research Future (part of Wantstats Research and Media Private Limited),

99 Hudson Street,5Th Floor, New York,

New York 10013

United States of America

Vascular Closure Devices Market to Be Driven by Rising Instances of Diseases Outlook by 2027

 Market Highlights

It is estimated that the global vascular closure devices market is expected to register a CAGR ~ 6.8% during the forecast period of 2018–2023. The global vascular closure devices market is expected to witness tremendous growth owing to the rising prevalence of numerous types of cardiovascular as well as neurovascular diseases. Other key factors such as the untapped market opportunities in emerging countries, growing investments by government organizations, increasing adoption rate of minimally invasive techniques are contributing towards the growth of the market. However, factors such as lack of trained medical professionals, and the post-operative complications are expected to curb the growth of the market during the forecast period.

Key Players:

Some of the key players in the global intraocular lens market are Abbott Laboratories, Terumo Corporation, Cardinal Health Inc., Cardiva Medical Inc., Morris Innovative, Inc., Medtronic plc, Essential Medical, Inc., Merit Medical Systems, Inc., TZ Medical, Inc., Vasorum Ltd., Transluminal Technologies LLC, Vascular Closure Systems, Inc., Vivasure Medical Ltd., among others.

Segmentations:

Currently, the global vascular closure devices market is dominated by numerous players. The major players in this market are involved in new product launches, strategic partnerships and collaborations to increase their product portfolio. For example, in June 2018, Biomerics, a medical device contract manufacturer announced the acquisition of FutureMatrix Interventional, Inc. The company aims to expand its portfolio of interventional catheters used in cardiovascular and urology fields, thus strengthening its position in the market.

The global vascular closure devices market is segmented on the basis of product type, access, procedures, application, and end user.

Regional Analysis:

On the regional basis, the vascular closure devices market in the Americas is predicted to dominate the market during the forecast period. The North American region holds substantial share in the global market. This owes to the rise in the government initiatives, and the increased prevalence of coronary diseases in these regions. For instance, according to the data published in 2015 by the American Heart Association (AHA), about one in 7 deaths in the US is caused by coronary heart disease. Also, numerous major players are based in the US, owing to which the US has become a center for innovation in the vascular closure devices market.

About US:

Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

Contact us:

Market Research Future (part of Wantstats Research and Media Private Limited),

99 Hudson Street,5Th Floor, New York,

New York 10013

United States of America

Sinus Dilation Devices Market Share Analysis, Strategies, Revenue and Forecasts to 2027

 Market Highlights

Sinus is also called as chronic rhinosinusitis; it is a condition in which cavities around nasal known as (sinuses) get inflamed and swollen for weeks. The people suffering from sinus may have symptoms such as nasal block, tenderness, swelling of the face, sore throat, nausea, fatigue or irritability, and pain in jaw and teeth.

The balloon sinus dilation Market is expected to witness tremendous growth owing to the rising demand for balloon sinuplasty or sinus dilation compare to conventional sinus surgeries, rising cases of bacterial infection and increasing adoption of sinus dilation devices for sinusitis. The sinus dilation devices market was estimated at USD 3,326 million in 2016 and expected to reach USD 5,778 million by 2027 at a CAGR of 8.1% from 2022 to 2027.

However, factors such as risks associated with the sinus surgery, low adoption of new advance devices related to sinus treatment may hinder the market growth during the forecast period.

Key Players

Some of the key players in the global sinus dilation devices market are Sklar Surgical Instruments (US), Accurate Surgical & Scientific Instruments(USA), Bausch & Lomb Incorporated (US), Entellus Medical Inc. (a subsidiary of Stryker) (US), Acclarent Inc. (a subsidiary of Johnson & Johnson) (US), Medtronic plc (Ireland), Smith & Nephew plc (UK), Intersect ENT Inc. (US), Olympus Corporation (Japan), Meril Life, Sciences Pvt. Ltd. (India), SinuSys Corporation (US), Jilin Coronado Medical Ltd. (China), and others.

Segmentation

The Global Sinus Dilation Devices Market is segmented on the basis of product, procedure, by patient type and end-user. The sinus dilation devices market, by product, is segmented into sinus stents, balloon dilation, endoscope, functional endoscopic sinus surgery (FESS) instruments set, and handheld instruments. The endoscope is sub-segmented into rhinoscopy and sinoscopy.

By procedure, the market is segmented into hybrid sinus dilation procedure, standalone sinus dilation procedures, and others.

On the basis of patient type, the market is segmented into pediatric and adults.

On the basis of end-user, the market is segmented into hospitals, ENT clinics, diagnostic centers, research centers, and others.

Regional Analysis

The Americas leads in the market owing to the increasing prevalence of rising incidence of bacterial infection, increasing research & development in sinus dilation devices and growing healthcare expenditure. According to the Centers for Disease Control and Prevention March 2022, data 11.0% of adults were diagnosed with sinusitis in the US. The increasing incidences of sinusitis support the sinus dilation devices market positively.

Europe is the second largest sinus dilation devices market during the forecast period. The increase in the prevalence of chronic sinus and increasing expenditure for sinus treatment may support the market growth. According to the National Center for Biotechnology Information 2022, the occurrence of chronic sinusitis in Europe and North America has been projected to be between 6% and 11%. It was also reported that around two-thirds of patients getting secondary care chronic sinusitis have nasal polyps. The increasing prevalence of chronic sinus supports the market growth in this region.

Asia-Pacific was estimated to be the fastest growing region for the global sinus dilation devices market in 2022. The market is expected to witness high growth owing to the rising prevalence of demand for sinus dilation over conventional sinus surgeries and increasing advance technology.

The Middle East and Africa holds the lowest share for sinus dilation devices market. However, the rising health care awareness programmers and availability of healthcare facilities are expected to influence the market in a positive way.

About US:

Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

Contact us:

Market Research Future (part of Wantstats Research and Media Private Limited),

99 Hudson Street,5Th Floor, New York,

New York 10013

United States of America

Clinical Decision Support Systems Market by Key Types, Detail Analysis and Forecasts To 2027

 Market Highlights

Sinus is also called as chronic rhinosinusitis; it is a condition in which cavities around nasal known as (sinuses) get inflamed and swollen for weeks. The people suffering from sinus may have symptoms such as nasal block, tenderness, swelling of the face, sore throat, nausea, fatigue or irritability, and pain in jaw and teeth.

The balloon sinus dilation Market is expected to witness tremendous growth owing to the rising demand for balloon sinuplasty or sinus dilation compare to conventional sinus surgeries, rising cases of bacterial infection and increasing adoption of sinus dilation devices for sinusitis. The sinus dilation devices market was estimated at USD 3,326 million in 2016 and expected to reach USD 5,778 million by 2027 at a CAGR of 8.1% from 2022 to 2027.

However, factors such as risks associated with the sinus surgery, low adoption of new advance devices related to sinus treatment may hinder the market growth during the forecast period.

Key Players

Some of the key players in the global sinus dilation devices market are Sklar Surgical Instruments (US), Accurate Surgical & Scientific Instruments(USA), Bausch & Lomb Incorporated (US), Entellus Medical Inc. (a subsidiary of Stryker) (US), Acclarent Inc. (a subsidiary of Johnson & Johnson) (US), Medtronic plc (Ireland), Smith & Nephew plc (UK), Intersect ENT Inc. (US), Olympus Corporation (Japan), Meril Life, Sciences Pvt. Ltd. (India), SinuSys Corporation (US), Jilin Coronado Medical Ltd. (China), and others.

Segmentation

The Global Sinus Dilation Devices Market is segmented on the basis of product, procedure, by patient type and end-user. The sinus dilation devices market, by product, is segmented into sinus stents, balloon dilation, endoscope, functional endoscopic sinus surgery (FESS) instruments set, and handheld instruments. The endoscope is sub-segmented into rhinoscopy and sinoscopy.

By procedure, the market is segmented into hybrid sinus dilation procedure, standalone sinus dilation procedures, and others.

On the basis of patient type, the market is segmented into pediatric and adults.

On the basis of end-user, the market is segmented into hospitals, ENT clinics, diagnostic centers, research centers, and others.

Regional Analysis

The Americas leads in the market owing to the increasing prevalence of rising incidence of bacterial infection, increasing research & development in sinus dilation devices and growing healthcare expenditure. According to the Centers for Disease Control and Prevention March 2022, data 11.0% of adults were diagnosed with sinusitis in the US. The increasing incidences of sinusitis support the sinus dilation devices market positively.

Europe is the second largest sinus dilation devices market during the forecast period. The increase in the prevalence of chronic sinus and increasing expenditure for sinus treatment may support the market growth. According to the National Center for Biotechnology Information 2022, the occurrence of chronic sinusitis in Europe and North America has been projected to be between 6% and 11%. It was also reported that around two-thirds of patients getting secondary care chronic sinusitis have nasal polyps. The increasing prevalence of chronic sinus supports the market growth in this region.

Asia-Pacific was estimated to be the fastest growing region for the global sinus dilation devices market in 2022. The market is expected to witness high growth owing to the rising prevalence of demand for sinus dilation over conventional sinus surgeries and increasing advance technology.

The Middle East and Africa holds the lowest share for sinus dilation devices market. However, the rising health care awareness programmers and availability of healthcare facilities are expected to influence the market in a positive way.

About US:

Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

Contact us:

Market Research Future (part of Wantstats Research and Media Private Limited),

99 Hudson Street,5Th Floor, New York,

New York 10013

United States of America

Hemophilia Treatment Market to Be Driven by Rising Instances of Diseases Outlook by 2027

 Market Scope

As per the reports by MRFR, the hemophilia treatment market is likely to project a robust CAGR of 6.10% during the review timeframe from 2022 to 2027.

Market Drivers

Hemophilia refers to a genetic disorder, usually hereditary, where the patient's blood lacks the needed proteins that help in blood coagulation. The condition could be severe, moderate, and mild. The global market for hemophilia treatment has been witnessing massive growth over recent years due to the increasing number of hemophilia cases, favorable government schemes & aggressive campaigning in several countries, and varied availability of therapies and medications. However, the growth of the hemophilia treatment cost hemophilia treatment market is anticipated to be hampered by the complications involved in the replacement therapies and higher costs associated with the recombinant products.

Competitive Analysis

The global market for hemophilia treatment has a strong competitive landscape with a wide number of players spread worldwide. The market players adopt several new strategies such as mergers, acquisitions, partnerships, and product development to grow their business. The list of leading players in the hemophilia treatment market includes companies such as F. Hoffmann-La Roche AG., Kedrion, Ferring B.V., Bayer AG, Baxter International Inc., Sanofi S.A., Octapharma AG, Novo Nordisk A/S, Pfizer, Inc., CSL Behring, Biogen Inc., Swedish Orphan Biovitrum AB, Takeda Pharmaceutical Co., Ltd., and many others.

Recent Developments

• October 2021- Takeda Pharmaceutical has signed an R&D alliance with Poseida Therapeutics to access the company's several non-viral gene therapy technologies. The primary six programs for the alliance come from Poseida's pipeline and comprise the biotech's most advanced gene therapy program, P-FVIII-101, a preclinical candidate for the inherited blood clotting disorder hemophilia A.

Segment Analysis

The global Hemophilia Treatment market for hemophilia treatment is divided into several segments based on diagnosis, treatment, product, distribution channel, and region.

Based on the diagnosis, the hemophilia treatment market is divided into gene therapy and replacement therapy.

Based on treatment, the global market for hemophilia treatment is divided into gene therapy, antifibrinolytic agents, desmopressin, recombinant coagulation factor concentrates, and plasma-derived coagulation factor concentrate.

Based on the product, the hemophilia treatment market is split into antifibrinolytic agents, desmopressin, von Willebrand factor, factor IX, factor VIII, recombinant coagulation factor concentrates, von willebrand factor, activated prothrombin complex concentrate, factor XIII, factor IX, factor VIII, and plasma-derived coagulation factor concentrates.

The hemophilia treatment market is bifurcated into retail pharmacy, hospital pharmacy, and others by distribution channel.

Regional Analysis

The global market for hemophilia treatment is studied mainly across five regions: North America, South America, Asia-Pacific, Europe, and the Middle East & Africa.

The North American regional hemophilia treatment market has held the leading position in the market globally. The major aspect driving the regional market's growth is the rising number of collaborations and partnerships with leading market players. In addition, the technological advances in the products and therapeutic methods and the growing awareness of the condition among people have also contributed to the regional market's growth over recent times. Association of America has extended its market growth by providing co-pay initiatives to acquire uninterrupted treatment. Lately, the developments in gene therapy, which aim for coagulation factors, have positively impacted the growth of the hemophilia treatment market in the North American region.

The Asia-pacific regional hemophilia treatment market is anticipated to secure the second position in the global market. The increasing favorable reimbursement policies are driving the growth of the regional market. China is emerging to be the major market in the region. It announced 80% of the Hemophilia treatment in the region had been covered under health insurance that recorded for more than USD 16,000 in 2012. Since then, the rise in favorable schemes has been seen in China.

About US:

Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

Contact us:

Market Research Future (part of Wantstats Research and Media Private Limited),

99 Hudson Street,5Th Floor, New York,

New York 10013

United States of America